nodes	percent_of_prediction	percent_of_DWPC	metapath
Levocabastine—NTSR2—Peptide GPCRs—TSHR—thyroid cancer	0.104	0.136	CbGpPWpGaD
Levocabastine—NTSR2—GPCR ligand binding—CALCB—thyroid cancer	0.0539	0.0705	CbGpPWpGaD
Levocabastine—NTSR2—Peptide ligand-binding receptors—SST—thyroid cancer	0.038	0.0497	CbGpPWpGaD
Levocabastine—NTSR2—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.0328	0.0428	CbGpPWpGaD
Levocabastine—NTSR2—GPCR downstream signaling—CALCB—thyroid cancer	0.0305	0.0398	CbGpPWpGaD
Levocabastine—NTSR2—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.03	0.0392	CbGpPWpGaD
Levocabastine—NTSR2—Signaling by GPCR—CALCB—thyroid cancer	0.0277	0.0362	CbGpPWpGaD
Levocabastine—NTSR2—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.0255	0.0333	CbGpPWpGaD
Levocabastine—NTSR2—GPCR ligand binding—TSHR—thyroid cancer	0.025	0.0326	CbGpPWpGaD
Levocabastine—NTSR2—GPCR ligand binding—PTCH1—thyroid cancer	0.0212	0.0277	CbGpPWpGaD
Levocabastine—NTSR2—GPCR ligand binding—SST—thyroid cancer	0.0194	0.0254	CbGpPWpGaD
Levocabastine—NTSR2—GPCR ligand binding—CALCA—thyroid cancer	0.0187	0.0244	CbGpPWpGaD
Levocabastine—NTSR2—Signaling Pathways—CALCB—thyroid cancer	0.0164	0.0214	CbGpPWpGaD
Levocabastine—NTSR2—Signaling Pathways—TRIM33—thyroid cancer	0.0155	0.0203	CbGpPWpGaD
Levocabastine—NTSR2—GPCR downstream signaling—TSHR—thyroid cancer	0.0141	0.0184	CbGpPWpGaD
Levocabastine—NTSR2—Signaling by GPCR—TSHR—thyroid cancer	0.0128	0.0167	CbGpPWpGaD
Levocabastine—NTSR2—Signaling by GPCR—PRKAR1A—thyroid cancer	0.0126	0.0165	CbGpPWpGaD
Levocabastine—Visual impairment—Vandetanib—thyroid cancer	0.0114	0.0484	CcSEcCtD
Levocabastine—NTSR2—GPCR downstream signaling—SST—thyroid cancer	0.011	0.0143	CbGpPWpGaD
Levocabastine—NTSR2—Signaling by GPCR—PTCH1—thyroid cancer	0.0109	0.0142	CbGpPWpGaD
Levocabastine—NTSR2—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.0108	0.0141	CbGpPWpGaD
Levocabastine—NTSR2—GPCR downstream signaling—CALCA—thyroid cancer	0.0106	0.0138	CbGpPWpGaD
Levocabastine—NTSR2—Signaling Pathways—TCF7L1—thyroid cancer	0.0103	0.0135	CbGpPWpGaD
Levocabastine—NTSR2—Signaling by GPCR—SST—thyroid cancer	0.00997	0.013	CbGpPWpGaD
Levocabastine—Lacrimation—Epirubicin—thyroid cancer	0.00995	0.0424	CcSEcCtD
Levocabastine—NTSR2—Signaling by GPCR—CALCA—thyroid cancer	0.00959	0.0125	CbGpPWpGaD
Levocabastine—NTSR2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.00926	0.0121	CbGpPWpGaD
Levocabastine—Lacrimation—Doxorubicin—thyroid cancer	0.00921	0.0392	CcSEcCtD
Levocabastine—Cough—Vandetanib—thyroid cancer	0.00895	0.0382	CcSEcCtD
Levocabastine—NTSR2—Signaling by GPCR—CDK1—thyroid cancer	0.00868	0.0113	CbGpPWpGaD
Levocabastine—Dry mouth—Vandetanib—thyroid cancer	0.00854	0.0364	CcSEcCtD
Levocabastine—HRH1—GPCR ligand binding—CALCB—thyroid cancer	0.00818	0.0107	CbGpPWpGaD
Levocabastine—NTSR2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.00787	0.0103	CbGpPWpGaD
Levocabastine—NTSR2—Signaling Pathways—TSHR—thyroid cancer	0.00757	0.00989	CbGpPWpGaD
Levocabastine—Dyspnoea—Vandetanib—thyroid cancer	0.00747	0.0318	CcSEcCtD
Levocabastine—NTSR2—Signaling Pathways—PRKAR1A—thyroid cancer	0.00745	0.00973	CbGpPWpGaD
Levocabastine—Stinging—Epirubicin—thyroid cancer	0.00722	0.0308	CcSEcCtD
Levocabastine—Fatigue—Vandetanib—thyroid cancer	0.00722	0.0308	CcSEcCtD
Levocabastine—Pain—Vandetanib—thyroid cancer	0.00716	0.0305	CcSEcCtD
Levocabastine—NTSR2—Signaling Pathways—MEN1—thyroid cancer	0.00712	0.0093	CbGpPWpGaD
Levocabastine—Erythema—Sorafenib—thyroid cancer	0.00692	0.0295	CcSEcCtD
Levocabastine—Stinging—Doxorubicin—thyroid cancer	0.00668	0.0285	CcSEcCtD
Levocabastine—NTSR2—Signaling Pathways—PTCH1—thyroid cancer	0.00644	0.00841	CbGpPWpGaD
Levocabastine—Lacrimation increased—Epirubicin—thyroid cancer	0.00635	0.0271	CcSEcCtD
Levocabastine—Cough—Sorafenib—thyroid cancer	0.00604	0.0257	CcSEcCtD
Levocabastine—Asthenia—Vandetanib—thyroid cancer	0.00601	0.0256	CcSEcCtD
Levocabastine—NTSR2—Signaling Pathways—SST—thyroid cancer	0.00589	0.00769	CbGpPWpGaD
Levocabastine—Lacrimation increased—Doxorubicin—thyroid cancer	0.00588	0.025	CcSEcCtD
Levocabastine—Dry mouth—Sorafenib—thyroid cancer	0.00576	0.0246	CcSEcCtD
Levocabastine—NTSR2—Signaling Pathways—CALCA—thyroid cancer	0.00567	0.00741	CbGpPWpGaD
Levocabastine—Rash—Vandetanib—thyroid cancer	0.00528	0.0225	CcSEcCtD
Levocabastine—Dermatitis—Vandetanib—thyroid cancer	0.00528	0.0225	CcSEcCtD
Levocabastine—Headache—Vandetanib—thyroid cancer	0.00525	0.0224	CcSEcCtD
Levocabastine—NTSR2—Signaling Pathways—CDK1—thyroid cancer	0.00513	0.0067	CbGpPWpGaD
Levocabastine—Dyspnoea—Sorafenib—thyroid cancer	0.00504	0.0215	CcSEcCtD
Levocabastine—Nausea—Vandetanib—thyroid cancer	0.00497	0.0212	CcSEcCtD
Levocabastine—HRH1—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00497	0.0065	CbGpPWpGaD
Levocabastine—Fatigue—Sorafenib—thyroid cancer	0.00487	0.0208	CcSEcCtD
Levocabastine—Pain—Sorafenib—thyroid cancer	0.00483	0.0206	CcSEcCtD
Levocabastine—Eye pain—Epirubicin—thyroid cancer	0.00471	0.0201	CcSEcCtD
Levocabastine—HRH1—GPCR downstream signaling—CALCB—thyroid cancer	0.00462	0.00604	CbGpPWpGaD
Levocabastine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.00455	0.00595	CbGpPWpGaD
Levocabastine—Eye pain—Doxorubicin—thyroid cancer	0.00435	0.0186	CcSEcCtD
Levocabastine—HRH1—Signaling by GPCR—CALCB—thyroid cancer	0.0042	0.00549	CbGpPWpGaD
Levocabastine—NTSR2—Signaling Pathways—NRG1—thyroid cancer	0.00412	0.00538	CbGpPWpGaD
Levocabastine—Asthenia—Sorafenib—thyroid cancer	0.00405	0.0173	CcSEcCtD
Levocabastine—HRH1—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.00387	0.00505	CbGpPWpGaD
Levocabastine—HRH1—GPCR ligand binding—TSHR—thyroid cancer	0.00379	0.00495	CbGpPWpGaD
Levocabastine—NTSR2—Signaling Pathways—TERT—thyroid cancer	0.0037	0.00483	CbGpPWpGaD
Levocabastine—Rash—Sorafenib—thyroid cancer	0.00356	0.0152	CcSEcCtD
Levocabastine—Dermatitis—Sorafenib—thyroid cancer	0.00356	0.0152	CcSEcCtD
Levocabastine—Headache—Sorafenib—thyroid cancer	0.00354	0.0151	CcSEcCtD
Levocabastine—NTSR2—Signaling Pathways—HIF1A—thyroid cancer	0.00354	0.00462	CbGpPWpGaD
Levocabastine—Nausea—Sorafenib—thyroid cancer	0.00336	0.0143	CcSEcCtD
Levocabastine—HRH1—GPCR ligand binding—PTCH1—thyroid cancer	0.00322	0.00421	CbGpPWpGaD
Levocabastine—HRH1—IL-4 Signaling Pathway—AKT1—thyroid cancer	0.00319	0.00416	CbGpPWpGaD
Levocabastine—NTSR2—Signaling by GPCR—NRAS—thyroid cancer	0.00311	0.00407	CbGpPWpGaD
Levocabastine—HRH1—GPCR ligand binding—SST—thyroid cancer	0.00295	0.00385	CbGpPWpGaD
Levocabastine—NTSR2—Signaling Pathways—BRAF—thyroid cancer	0.00293	0.00383	CbGpPWpGaD
Levocabastine—Pharyngitis—Epirubicin—thyroid cancer	0.00292	0.0124	CcSEcCtD
Levocabastine—HRH1—GPCR ligand binding—CALCA—thyroid cancer	0.00284	0.00371	CbGpPWpGaD
Levocabastine—Visual impairment—Epirubicin—thyroid cancer	0.00283	0.0121	CcSEcCtD
Levocabastine—Pharyngitis—Doxorubicin—thyroid cancer	0.0027	0.0115	CcSEcCtD
Levocabastine—NTSR2—Signaling by GPCR—KRAS—thyroid cancer	0.00268	0.0035	CbGpPWpGaD
Levocabastine—Visual impairment—Doxorubicin—thyroid cancer	0.00262	0.0112	CcSEcCtD
Levocabastine—Erythema—Epirubicin—thyroid cancer	0.00256	0.0109	CcSEcCtD
Levocabastine—HRH1—Signaling Pathways—CALCB—thyroid cancer	0.00248	0.00324	CbGpPWpGaD
Levocabastine—Erythema—Doxorubicin—thyroid cancer	0.00237	0.0101	CcSEcCtD
Levocabastine—HRH1—Signaling Pathways—TRIM33—thyroid cancer	0.00235	0.00307	CbGpPWpGaD
Levocabastine—NTSR2—Signaling by GPCR—HRAS—thyroid cancer	0.00228	0.00298	CbGpPWpGaD
Levocabastine—Cough—Epirubicin—thyroid cancer	0.00223	0.00951	CcSEcCtD
Levocabastine—NTSR2—GPCR downstream signaling—AKT1—thyroid cancer	0.00222	0.0029	CbGpPWpGaD
Levocabastine—HRH1—GPCR downstream signaling—TSHR—thyroid cancer	0.00214	0.0028	CbGpPWpGaD
Levocabastine—NTSR2—Signaling Pathways—CCND1—thyroid cancer	0.00214	0.00279	CbGpPWpGaD
Levocabastine—Dry mouth—Epirubicin—thyroid cancer	0.00213	0.00908	CcSEcCtD
Levocabastine—Cough—Doxorubicin—thyroid cancer	0.00207	0.0088	CcSEcCtD
Levocabastine—NTSR2—Signaling Pathways—PTEN—thyroid cancer	0.00206	0.00269	CbGpPWpGaD
Levocabastine—NTSR2—Signaling by GPCR—AKT1—thyroid cancer	0.00201	0.00263	CbGpPWpGaD
Levocabastine—Dry mouth—Doxorubicin—thyroid cancer	0.00197	0.0084	CcSEcCtD
Levocabastine—HRH1—Signaling by GPCR—TSHR—thyroid cancer	0.00194	0.00254	CbGpPWpGaD
Levocabastine—HRH1—Signaling by GPCR—PRKAR1A—thyroid cancer	0.00191	0.0025	CbGpPWpGaD
Levocabastine—Dyspnoea—Epirubicin—thyroid cancer	0.00186	0.00793	CcSEcCtD
Levocabastine—Somnolence—Epirubicin—thyroid cancer	0.00186	0.00791	CcSEcCtD
Levocabastine—NTSR2—Signaling Pathways—NRAS—thyroid cancer	0.00184	0.0024	CbGpPWpGaD
Levocabastine—Fatigue—Epirubicin—thyroid cancer	0.0018	0.00767	CcSEcCtD
Levocabastine—Pain—Epirubicin—thyroid cancer	0.00179	0.00761	CcSEcCtD
Levocabastine—Dyspnoea—Doxorubicin—thyroid cancer	0.00172	0.00734	CcSEcCtD
Levocabastine—Somnolence—Doxorubicin—thyroid cancer	0.00172	0.00732	CcSEcCtD
Levocabastine—Fatigue—Doxorubicin—thyroid cancer	0.00167	0.0071	CcSEcCtD
Levocabastine—HRH1—GPCR downstream signaling—SST—thyroid cancer	0.00166	0.00218	CbGpPWpGaD
Levocabastine—HRH1—Signaling by GPCR—PTCH1—thyroid cancer	0.00165	0.00216	CbGpPWpGaD
Levocabastine—Pain—Doxorubicin—thyroid cancer	0.00165	0.00704	CcSEcCtD
Levocabastine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.00163	0.00213	CbGpPWpGaD
Levocabastine—HRH1—GPCR downstream signaling—CALCA—thyroid cancer	0.0016	0.00209	CbGpPWpGaD
Levocabastine—NTSR2—Signaling Pathways—KRAS—thyroid cancer	0.00158	0.00207	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—TCF7L1—thyroid cancer	0.00157	0.00205	CbGpPWpGaD
Levocabastine—HRH1—Signaling by GPCR—SST—thyroid cancer	0.00151	0.00198	CbGpPWpGaD
Levocabastine—Asthenia—Epirubicin—thyroid cancer	0.0015	0.00638	CcSEcCtD
Levocabastine—HRH1—Signaling by GPCR—CALCA—thyroid cancer	0.00146	0.0019	CbGpPWpGaD
Levocabastine—NTSR2—Signaling Pathways—TP53—thyroid cancer	0.00141	0.00184	CbGpPWpGaD
Levocabastine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.00141	0.00184	CbGpPWpGaD
Levocabastine—Asthenia—Doxorubicin—thyroid cancer	0.00139	0.00591	CcSEcCtD
Levocabastine—NTSR2—Signaling Pathways—HRAS—thyroid cancer	0.00135	0.00176	CbGpPWpGaD
Levocabastine—HRH1—Signaling by GPCR—CDK1—thyroid cancer	0.00132	0.00172	CbGpPWpGaD
Levocabastine—Rash—Epirubicin—thyroid cancer	0.00132	0.00561	CcSEcCtD
Levocabastine—Dermatitis—Epirubicin—thyroid cancer	0.00132	0.0056	CcSEcCtD
Levocabastine—Headache—Epirubicin—thyroid cancer	0.00131	0.00557	CcSEcCtD
Levocabastine—Nausea—Epirubicin—thyroid cancer	0.00124	0.00528	CcSEcCtD
Levocabastine—Rash—Doxorubicin—thyroid cancer	0.00122	0.00519	CcSEcCtD
Levocabastine—Dermatitis—Doxorubicin—thyroid cancer	0.00122	0.00519	CcSEcCtD
Levocabastine—Headache—Doxorubicin—thyroid cancer	0.00121	0.00516	CcSEcCtD
Levocabastine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.00119	0.00156	CbGpPWpGaD
Levocabastine—NTSR2—Signaling Pathways—AKT1—thyroid cancer	0.00119	0.00155	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—TSHR—thyroid cancer	0.00115	0.0015	CbGpPWpGaD
Levocabastine—Nausea—Doxorubicin—thyroid cancer	0.00115	0.00489	CcSEcCtD
Levocabastine—HRH1—Signaling Pathways—PRKAR1A—thyroid cancer	0.00113	0.00148	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—MEN1—thyroid cancer	0.00108	0.00141	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—PTCH1—thyroid cancer	0.000976	0.00128	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—SST—thyroid cancer	0.000893	0.00117	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—CALCA—thyroid cancer	0.00086	0.00112	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—CDK1—thyroid cancer	0.000778	0.00102	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—NRG1—thyroid cancer	0.000625	0.000816	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—TERT—thyroid cancer	0.000561	0.000733	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—HIF1A—thyroid cancer	0.000536	0.000701	CbGpPWpGaD
Levocabastine—HRH1—Signaling by GPCR—NRAS—thyroid cancer	0.000472	0.000617	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—BRAF—thyroid cancer	0.000444	0.00058	CbGpPWpGaD
Levocabastine—HRH1—Signaling by GPCR—KRAS—thyroid cancer	0.000407	0.000531	CbGpPWpGaD
Levocabastine—HRH1—Signaling by GPCR—HRAS—thyroid cancer	0.000346	0.000452	CbGpPWpGaD
Levocabastine—HRH1—GPCR downstream signaling—AKT1—thyroid cancer	0.000336	0.000439	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—CCND1—thyroid cancer	0.000324	0.000424	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—PTEN—thyroid cancer	0.000313	0.000409	CbGpPWpGaD
Levocabastine—HRH1—Signaling by GPCR—AKT1—thyroid cancer	0.000305	0.000399	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—NRAS—thyroid cancer	0.000279	0.000365	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—KRAS—thyroid cancer	0.00024	0.000314	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—TP53—thyroid cancer	0.000214	0.000279	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—HRAS—thyroid cancer	0.000204	0.000267	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—AKT1—thyroid cancer	0.00018	0.000236	CbGpPWpGaD
